GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Price-to-Owner-Earnings

Sutro Biopharma (FRA:S09) Price-to-Owner-Earnings : (As of Sep. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Price-to-Owner-Earnings?

As of today (2024-09-24), Sutro Biopharma's share price is €3.34. Sutro Biopharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sutro Biopharma's Price-to-Owner-Earnings or its related term are showing as below:


FRA:S09's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.525
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-24), Sutro Biopharma's share price is €3.34. Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.70. Therefore, Sutro Biopharma's PE Ratio for today is At Loss.

As of today (2024-09-24), Sutro Biopharma's share price is €3.34. Sutro Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.89. Therefore, Sutro Biopharma's PE Ratio without NRI for today is At Loss.


Sutro Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Sutro Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Price-to-Owner-Earnings Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Sutro Biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sutro Biopharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Sutro Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Price-to-Owner-Earnings falls into.



Sutro Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sutro Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.34/-1.22
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sutro Biopharma  (FRA:S09) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sutro Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Headlines

No Headlines